BRCA1相关乳腺癌的临床前小鼠模型
Preclinical mouse models for BRCA1-associated breast cancer.
作者信息
Drost R M, Jonkers J
机构信息
Division of Molecular Biology, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam 1066 CX, The Netherlands.
出版信息
Br J Cancer. 2009 Nov 17;101(10):1651-7. doi: 10.1038/sj.bjc.6605350. Epub 2009 Sep 29.
Abstract
A substantial part of all hereditary breast cancer cases is caused by BRCA1 germline mutations. In this review, we will discuss the insights into BRCA1 functions that we obtained from mouse models with conventional and conditional mutations in Brca1. The most advanced models closely resemble human BRCA1-related breast cancer and may therefore be useful for addressing clinically relevant questions.
摘要
所有遗传性乳腺癌病例中有很大一部分是由BRCA1种系突变引起的。在本综述中，我们将讨论从Brca1具有常规和条件性突变的小鼠模型中获得的关于BRCA1功能的见解。最先进的模型与人类BRCA1相关乳腺癌非常相似，因此可能有助于解决临床相关问题。
相似文献
1
Preclinical mouse models for BRCA1-associated breast cancer.
Br J Cancer. 2009 Nov 17;101(10):1651-7. doi: 10.1038/sj.bjc.6605350. Epub 2009 Sep 29.
2
Studying therapy response and resistance in mouse models for BRCA1-deficient breast cancer.
J Mammary Gland Biol Neoplasia. 2011 Apr;16(1):41-50. doi: 10.1007/s10911-011-9199-z. Epub 2011 Feb 18.
3
BRCA genes: lessons learned from experimental and clinical cancer.
Ann Oncol. 2011 Jan;22 Suppl 1:i7-10. doi: 10.1093/annonc/mdq659.
4
BRCA1-associated tumorigenesis: what have we learned from knockout mice?
Trends Genet. 2001 Oct;17(10):S18-22. doi: 10.1016/s0168-9525(01)02451-9.
5
Mouse models of BRCA1 and their application to breast cancer research.
Cancer Metastasis Rev. 2013 Jun;32(1-2):25-37. doi: 10.1007/s10555-012-9403-7.
6
Special considerations in mouse models of breast cancer.
Breast Dis. 2007;28:29-38. doi: 10.3233/bd-2007-28104.
7
Generation and analysis of Brca1 conditional knockout mice.
Methods Mol Biol. 2004;280:185-200. doi: 10.1385/1-59259-788-2:185.
8
Breast cancer genes: therapeutic strategies.
Ann N Y Acad Sci. 1997 Dec 29;833:34-41. doi: 10.1111/j.1749-6632.1997.tb48590.x.
9
Emerging roles of BRCA1 in transcriptional regulation and DNA repair.
J Cell Physiol. 1999 Dec;181(3):385-92. doi: 10.1002/(SICI)1097-4652(199912)181:3<385::AID-JCP2>3.0.CO;2-4.
10
Genetically engineered rat models for breast cancer.
Breast Dis. 2007;28:53-61. doi: 10.3233/bd-2007-28106.
引用本文的文献
1
Epigenetic scars of Brca1 loss point toward breast cancer cell of origin.
Nat Genet. 2024 Dec;56(12):2594-2595. doi: 10.1038/s41588-024-02021-0.
2
The Tumor Suppressor BRCA1/2, Cancer Susceptibility and Genome Instability in Gynecological and Mammary Cancers.
Asian Pac J Cancer Prev. 2023 Sep 1;24(9):3139-3153. doi: 10.31557/APJCP.2023.24.9.3139.
3
Brca1 rat is a novel model of human BRCA1 deficiency displaying susceptibility to radiation-induced mammary cancer.
Cancer Sci. 2022 Oct;113(10):3362-3375. doi: 10.1111/cas.15485. Epub 2022 Aug 21.
4
Loss of function of BRCA1 promotes EMT in mammary tumors through activation of TGFβR2 signaling pathway.
Cell Death Dis. 2022 Mar 2;13(3):195. doi: 10.1038/s41419-022-04646-7.
5
Pathogenesis of Triple-Negative Breast Cancer.
Annu Rev Pathol. 2022 Jan 24;17:181-204. doi: 10.1146/annurev-pathol-042420-093238.
6
Histological Findings of Mammary Gland Development and Risk of Breast Cancer in Mutant Mouse Models.
J Breast Cancer. 2021 Oct;24(5):455-462. doi: 10.4048/jbc.2021.24.e44. Epub 2021 Oct 5.
7
GATA3 functions downstream of BRCA1 to suppress EMT in breast cancer.
Theranostics. 2021 Jul 13;11(17):8218-8233. doi: 10.7150/thno.59280. eCollection 2021.
8
Mouse Models for Deciphering the Impact of Homologous Recombination on Tumorigenesis.
Cancers (Basel). 2021 Apr 25;13(9):2083. doi: 10.3390/cancers13092083.
9
and Deficiency Sensitizes Ovarian Cancer to Platinum Therapy and Confers Better Prognosis.
Biomedicines. 2021 Feb 18;9(2):207. doi: 10.3390/biomedicines9020207.
10
ENCORE: A Visualization Tool for Insight into Circadian Omics.
ACM BCB. 2019 Sep;2019:5-14. doi: 10.1145/3307339.3342137.
本文引用的文献
1
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
N Engl J Med. 2009 Jul 9;361(2):123-34. doi: 10.1056/NEJMoa0900212. Epub 2009 Jun 24.
2
High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
Cancer Res. 2009 Apr 15;69(8):3625-33. doi: 10.1158/0008-5472.CAN-08-3426. Epub 2009 Mar 31.
3
High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors.
Cancer Res. 2009 Jan 15;69(2):663-71. doi: 10.1158/0008-5472.CAN-08-1560.
4
E3 ligase activity of BRCA1 is not essential for mammalian cell viability or homology-directed repair of double-strand DNA breaks.
Proc Natl Acad Sci U S A. 2008 Dec 30;105(52):20876-81. doi: 10.1073/pnas.0811203106. Epub 2008 Dec 16.
5
Identification and functional analysis of novel BRCA1 transcripts, including mouse Brca1-Iris and human pseudo-BRCA1.
Breast Cancer Res Treat. 2010 Jan;119(1):239-47. doi: 10.1007/s10549-008-0256-2. Epub 2008 Dec 9.
6
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.
Proc Natl Acad Sci U S A. 2008 Nov 4;105(44):17079-84. doi: 10.1073/pnas.0806092105. Epub 2008 Oct 29.
7
"BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.
J Clin Oncol. 2008 Dec 1;26(34):5530-6. doi: 10.1200/JCO.2008.16.1703. Epub 2008 Oct 27.
8
Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients.
Breast Cancer Res Treat. 2009 May;115(2):359-63. doi: 10.1007/s10549-008-0128-9. Epub 2008 Jul 23.
9
Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors.
Cancer Res. 2008 May 1;68(9):3243-50. doi: 10.1158/0008-5472.CAN-07-5480.
10
The basal-like mammary carcinomas induced by Brca1 or Bard1 inactivation implicate the BRCA1/BARD1 heterodimer in tumor suppression.
Proc Natl Acad Sci U S A. 2008 May 13;105(19):7040-5. doi: 10.1073/pnas.0711032105. Epub 2008 Apr 28.
Zotero 插件